Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MYPET
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Farletuzumab-SPP-DM1
|
|||||
| Synonyms |
Farletuzumab SPP DM1
Click to Show/Hide
|
|||||
| Organization |
ImmunoGen, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Cervical cancer [ICD11:2C77]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.5-4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Farletuzumab
|
Antibody Info | ||||
| Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Mertansine
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.